Talent & Expertise Open Innovation Technologies International Partnerships
Total Page:16
File Type:pdf, Size:1020Kb
MEET, SHARE AND WORK WITH BIOWIN OPEN INNOVATION TALENT & EXPERTISE TECHNOLOGIES INTERNATIONAL PARTNERSHIPS 1 Photography by Michel Houet 2 Design by Hoet&Hoet Where Science + Business means Partnerships BioWin is the health competitiveness cluster of Wallonia (Belgium), the region located just South of Brussels. Wallonia, also known as one of the most innova- tive biotech hubs of Europe, is a unique area of Belgium that is home to more than 116 health companies specializing in health biotechnology and medical technologies. Domains covered by these companies include biopharmacy, cell therapy, radiopharmacy, diagnostics, biotech products, services (CRO, CMO, bio- informatics), medical devices and medical equipment. Major strengths in the fi eld of biotechnology linked to health include: excellence in academic and in- dustrial research; a unique academic and industrial collaborative network; a high concentration of university hospitals (Belgium has the world’s highest proportion of clinical trials per capita with the fastest approval for phase 1 clini- cal trials in Europe: 2 weeks!); and a broad offering of science parks with incu- bation and innovation centers at a reasonable cost. Making Wallonia’s location of utmost importance. Created in July 2006, BioWin saw an opportunity nestled among the framework of a major regional socioeconomic program. Focusing on the health sector, the development of this competitiveness cluster aims to provide regional economic growth by creating companies, extending existing ones and by creating jobs in the region. Its initiative was and still is to federate all stakeholders from Wallo- nia who are contributing to innovation and training in the fi eld of biotechnology and health, and who have the ambition to accelerate innovation, by encourag- ing universities and industry (mostly SMEs) to partner with one another. In these partnerships, industry is given the leading role to ensure that inno- vative products/services are created for new global markets. To foster these public–private partnerships between universities, companies (both small and large) and research centers, the regional government launches annual calls for projects in which BioWin manages the initial set-up and ensure that they are operational on an international level. 1 Companies- member of BioWin Wallonia has fully-integrated value chains in cutting-edge technological domains such as: Biopharma, Radiopharma, Regenerative Medicine and In Vitro Diagnostics. Employment split (%) by activity sector (116 innovative companies - without Baxter, GSK Vaccines and UCB). [21%] MEDICAL EQUIPEMENTS [9%] CONTRACT RESEARCH MEDICAL DEVICES ORGANISATION (CRO) INSTRUMENTS [9%] BIOTECH PRODUCTS [20%] SUPPORT SERVICES BIOINFORMATICS IT SERVICES [11%] DIAGNOSTICS [13%] BIOPHARMA [17%] CONTRACT MANUFACTURING ORGANIZATION (CMO) 2 source: M5 Generated an estimated annual turnover of 4.4 billion euros and employing approximately 14,300 people BioWin remains one of the top European compe- titiveness clusters to date, rapidly acquiring worldwide recognition. The Wallonia region alone is home to world leaders such as GSK Vaccines (...), UCB (CNS and Immunology), Baxter (biopharmaceutical and medical devices), IBA (cancer, radio-diagnostic and therapy), and Eurogentec-Kaneka (biotechno- logy products and diagnostics). One - third of the workforce of these com- panies is employed in R & D. This proportion is even higher among the ever- important innovative Small and Medium Enterprises (SME’s) in the region. With over 400 public and private R & D centers, employing more than 11,000 researchers, private expenses in R&D amount to an astonishing 900 million Euros per year. It is important to note that three academies involving several universities have been created in order to federate the efforts in higher education and academic research: the Académie Universitaire Louvain comprising the Univer- sité Catholique de Louvain (UCL, Louvain) and the Université de Namur; the Académie Universitaire Wallonie–Bruxelles comprising the Université Libre de Bruxelles (ULB, Brussels) and the Université de Mons (UMONS, Mons); and the Académie Universitaire Wallonie–Europe comprising the University of Liège (ULg, Liège). In addition to the universities, the region is also home to prestigious research institutes including, among several others, the Ludwig Institute of Cancer Research (LICR), the GIGA (Liège), the Institute of Medical Immunology (IMI), or the Christian de Duve Institute of Cellular Pathology (ICP), Winner of the Nobel prize in Medicine. In 2009, Wallonia and regional stakeholders launched an initiative to sup- port excellence in basic research conducting to potential technology trans- fers in the fi elds of medical, pharmaceutical and veterinary biotechnologies: WELBIO, the institute for Walloon excellence in life sciences and biotechno- logy. In 2012, BioWin opened a PartnerPort in the Biopark Incubator 2. This service aims to provide the partners who are willing to explore collaborative opportunities in Wallonia with complete offi ce facilities as well as BioWin support to access health sector key players. BioWin today = 510 members: 116 companies Turn over: 4,4 billion Euros/year Employment: 14,300 direct jobs Private investments in R&D: 900 million Euros/year 3 university academia 400 research units from 3 universities academia 11,000 researchers Investments (non R&D): 288 million Euros/year 3 The BioWin core activities are centered on: 1 Open Innovation: to foster collaborative R&D projects favorable to scientifi c excellence and innovation leadership in Wallonia. 2 Talents and Expertise: to train, attract, develop and retain a human nucleus of excellence in Wallonia 3 Technology: to help to establish the setting up of collective infrastructures and technological platforms 4 International partnerships: to internationally promote the strengths of Wallonia in the area of health biotechnology and medical technologies 4 1 Open Innovation There are currently 27 Research & Development collaborative projects between industry and academia. The BioWin initiative is to seek out those projects that are not only at the forefront of innovation but that provide a strong sensible business plan with high governing standards. BioWin determines the scope of the calls for projects and helps in the formation of consortia via network- ing activities. The minimum consortium comprises two academic laboratories from two different universities and two companies, including at least one SME. A project leader from one of the private companies is also chosen. Projects are selected by an international jury that is appointed by BioWin. The BioWin jury (selected according to project criteria) evaluates the scientifi c excellence, as well as the economic potential, of the projects and recommends the most promising ones to the BioWin board. In this aspect, only the best projects, which are able to compete on an international level are fi nally recommended for fi - nancing to the regional government. Approximately eighteen months following the implementation of the project, BioWin and the jury review and evaluate the project. In efforts to maintain good governance practice, these midterm evalu- ations are required by BioWin to determine whether or not the project is on tar- get and moving in the right direction. Through regional funding the project will receive an estimated 3-4 million Euros over the course of 4 years. Since 2006, fi nancial support to the 27 ongoing projects, received from both public and pri- vate investors, has reached an outstanding 88,6 million euros. While the university receives full funding, the large and small companies are re- sponsible for a portion of their investment, emphasizing the importance of the industry’s involvement in the program and it’s development. This fi nancial com- mitment reinforces commercial valorization giving rise to license agreements, creation of spin-offs, joint ventures, etc... In order to maintain the capacities in innovation, cross-fertilization (cross wise techniques) within the region is highly favored. Defi ned by the interaction between biomedical sciences and other technologies, this allows for the development of existing and innovative avenues in the industry. By combining mechanical engi- neering, logistics, photonics or ICT with biomedical sciences, new sectors such as radiopharmacy, biologistics, biophotonics or e-health are rapidly developing. - 27 R&D Collaborative projects - Commercial valorisation - Cross wise techniques 5 - Specifi c training courses - In-company trainingships - Multidisciplinary collaborations 2 Talents & Expertise One of BioWin’s initiatives is to provide innovative training programs that are specifi cally tailored to the needs of companies. BioWin prepares for the future with open innovation at a regional level by helping businesses needing highly- skilled staff fi nd the right training programs and expertise. Several sessions each year are organized on subjects as varied as quality control, clinical studies, intellectual property and entrepreneurship. This project aims to update and/or upgrade the know-how of employees. However, these sessions are also open to students, university professors and job seekers wishing to broaden their knowl- edge in a particular sector. BioWin shares this initiative with other clusters in the Wallonia region. Another initiative builds bridges between universities and industry via in- company traineeships for students as well as through continued education pro- grams for professionals.